A new clinical trial will compare the use of Carthera’s SonoCloud-9 implantable ultrasound device plus chemotherapy to standard-of-care therapies in patients with glioblastoma.
The study will enroll 560 participants at 40 sites throughout the US and Europe.
As Executive Director, Bob Smith will oversee Foundation activities related to the gene therapy, cancer immunotherapy, veterinary medicine, neurodegenerative diseases, and FUS Partners programs.
Mr. Smith was formerly senior vice president of the Global Gene Therapy Business at Pfizer, Inc.
In a recent radio interview, John shared his story of undergoing focused ultrasound to treat the symptoms of his Parkinson’s disease.
The 3-minute segment also features Foundation Chairman Neal F. Kassell, MD, discussing how the technology could impact many more areas of medicine, including cancer.
The International OCD Foundation is offering $500,000 in research funding through two grant types related to advancing treatment of obsessive-compulsive disorder (OCD).
“There has been considerable research at the University of Virginia and now Virginia Tech. We are positioning the entire Commonwealth of Virginia on the leading edge of high-tech development in focused ultrasound.”
‒ Neal F. Kassell, MD, in Virginia Public Radio Interview